Paloma Partners Management CO Nektar Therapeutics Transaction History

Paloma Partners Management CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $49,706 - $101,069	55,229 New	55,229 $68,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $2.7 Million - $5.22 Million	-186,538 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $1.17 Million - $1.71 Million	74,034 Added 65.81%	186,538 $4.03 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $1.9 Million - $4.08 Million	112,504 New	112,504 $2.05 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $898,506 - $1.67 Million	-29,527 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $17.9 Million - $26.4 Million	-385,773 Reduced 92.89%	29,527 $1.8 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $19.1 Million - $43.2 Million	413,170 Added 19397.65%	415,300 $20.3 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $624,339 - $1.18 Million	-10,877 Reduced 83.62%	2,130 $227,000
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $299,421 - $786,923	13,007	13,007 $777,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $178M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.